Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Approaches to the treatment of some of the troublesome manifestations of sarcoidosis.
Journal of internal medicine·2014
Same author
Optimal scoring of serial change on chest radiography in sarcoidosis.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2011
Same author
Idiopathic pulmonary fibrosis trials: recommendations for the jury.
The European respiratory journal·2011
Related Experiment Video
Updated: Jul 18, 2026
06:29
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
Idiopathic pulmonary fibrosis
1Royal Brompton National Heart and Lung Hospital, London, United Kingdom.
Annual Review of Medicine
|January 1, 1993
Summary
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with limited treatment options. Emerging diagnostic and therapeutic strategies offer new hope for managing IPF.
Area of Science:
- Pulmonology and Respiratory Medicine
- Medical Imaging
- Molecular and Cellular Biology
Background:
- Idiopathic pulmonary fibrosis (IPF) presents a significant mortality rate, with 50% of patients dying within five years.
- Current treatments for IPF are largely ineffective, and disease incidence is rising globally.
- There is a critical unmet need for novel diagnostic and therapeutic approaches to IPF.
Purpose of the Study:
- To explore innovative diagnostic techniques for idiopathic pulmonary fibrosis.
- To review emerging therapeutic strategies for idiopathic pulmonary fibrosis management.
- To highlight the potential of integrating advanced imaging and molecular biology in IPF care.
Main Methods:
- Review of recent advancements in medical imaging relevant to IPF diagnosis.
Main Results:
- Advanced imaging techniques show promise for earlier and more accurate IPF detection.
- Molecular and cellular biology research is identifying new pathways for IPF intervention.
- Combination strategies integrating imaging and molecular approaches may offer improved IPF outcomes.
Conclusions:
- New imaging and molecular biology advances are paving the way for improved IPF diagnosis.
- Novel therapeutic strategies are emerging to modulate the IPF disease process.
- Integrated approaches hold potential for transforming the management of idiopathic pulmonary fibrosis.